联合PARP与雄激素受体抑制治疗转移性去势抵抗性前列腺癌的生物学基础
综述总结临床前证据,提示雄激素受体(AR)与聚[ADP-核糖]聚合酶(PARP)存在相互作用,可独立于同源重组修复(HRR)缺陷被治疗利用;四项随机研究中有三项显示,在转移性前列腺癌患者中加用PARP抑制剂可显著增强抗肿瘤活性,与HRR基因改变无关。
要点
- 临床前证据提示AR可调控HRR基因、PARP与AR活性相互影响。
- AR与PARP的相互作用可独立于肿瘤HRR缺陷被治疗利用。
- 四项随机研究中有三项显示加用PARP抑制剂显著增强抗肿瘤活性。
核心结论
- 临床前证据支持PARP抑制剂与AR通路抑制剂联合,可能解释临床观察到的疗效。
研究设计与样本
- 综述总结支持PARP与AR抑制剂联合的现有临床前证据,并讨论其与临床疗效的关系。
主要发现
- 临床前证据提示AR调控HRR基因、PARP与AR活性相互影响、BRCA2与视网膜母细胞瘤基因在人基因组中共定位。
- 四项随机研究中有三项显示,在转移性前列腺癌男性中加用PARP抑制剂使抗肿瘤活性显著增加,与HRR基因改变无关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
For about a decade, poly [ADP ribose] polymerases (PARP) inhibitors have been used almost exclusively to treat tumours that are deficient in one of the BRCA genes. In advanced prostate cancer, which is largely driven by the activity of the androgen receptor (AR), accumulating preclinical evidence has suggested an interplay between the AR and PARP, which could be therapeutically exploited independently of defects in the tumour's DNA homologous recombination repair (HRR) machinery. This includes the regulation of HRR genes by the AR, a mutual influence between the activities of PARP and the AR, and the co-localisation of BRCA2 to the retinoblastoma gene in the human genome. Based on these findings, randomised clinical trials have been initiated to study the addition of a PARP inhibitor to AR pathway inhibitor therapy. Three of four randomised studies demonstrated a significantly increased anti-tumour activity in men with metastatic prostate cancer, irrespective of HRR gene alterations. In this review, we summarise the available preclinical evidence that provides the rationale for the combination of inhibitors for PARP and the AR and discuss how it might contribute to the efficacy observed in the clinic.
引用
- Agarwal N, Zhang T, Efstathiou E, et al. The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer. Eur J Cancer. 2023. PMID: 37672815. doi:10.1016/j.ejca.2023.113249
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。